GBT Announces Participation at the Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Global Blood Therapeutics (GBT) will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on August 10, 2022, at 2:20 p.m. E.T. The event will be live-streamed on GBT's website, with an archived replay available for one month. GBT, founded in 2011, focuses on developing treatments for sickle cell disease (SCD). The company has launched Oxbryta (voxelotor), the first FDA-approved medicine targeting SCD by inhibiting sickle hemoglobin polymerization and is advancing other pipeline programs aimed at improving care for SCD patients.

Positive

• Participation in the Wedbush PacGrow Healthcare Conference may enhance visibility and investor interest.
• GBT is dedicated to developing transformative treatments for sickle cell disease, leveraging innovative solutions in its pipeline.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022, at 2:20 p.m. E.T.

The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com

 

FAQ

What is the date of GBT's participation in the Wedbush PacGrow Healthcare Conference?

GBT will participate in the conference on August 10, 2022.

Where can I watch GBT's fireside chat?

The fireside chat will be webcast live on GBT's website.

What is Oxbryta and its significance for GBT?

Oxbryta (voxelotor) is the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, addressing the root cause of sickle cell disease.

What stage is GBT's current pipeline program in for sickle cell disease?

GBT is advancing inclacumab, a P-selectin inhibitor, in Phase 3 development.